table of content
Table of Contents
Post-pandemic Era-Global Drugs for Non-Small Cell Lung Cancer Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Radiofrequency Ablation (RFA) -Product Introduction and Major Company
1.1.2 Radiation Therapy -Product Introduction and Major Company
1.1.3 Chemotherapy -Product Introduction and Major Company
1.1.4 Targeted Therapies -Product Introduction and Major Company
1.1.5 Immunotherapy -Product Introduction and Major Company
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Five-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
2.1 Regional Market Share in Terms of Sales (2018 & 2022 & 2026)
2.2 Regional Market Share in Terms of Revenue (2018 & 2022 & 2026)
2.3 Regional Market Share in Terms of Consumption (2018 & 2022 & 2026)
3 Global Drugs for Non-Small Cell Lung Cancer Market Assessment by Type
3.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Type (2018-2028)
3.2 Global Drugs for Non-Small Cell Lung Cancer Revenue by Type (2018-2028)
3.3 North America Drugs for Non-Small Cell Lung Cancer Sales and Revenue by Type (2018-2028)
3.4 Asia Drugs for Non-Small Cell Lung Cancer Sales and Revenue by Type (2018-2028)
3.5 Europe Drugs for Non-Small Cell Lung Cancer Sales and Revenue by Type (2018-2028)
3.6 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Sales and Revenue by Type (2018-2028)
3.7 South America Drugs for Non-Small Cell Lung Cancer Sales and Revenue by Type (2018-2028)
4 Historical & Forecast Global Drugs for Non-Small Cell Lung Cancer Market Assessment by Application
4.1 Global Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
4.2 North America Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
4.3 Asia Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
4.4 Europe Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
4.5 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
4.6 South America Drugs for Non-Small Cell Lung Cancer Consumption and Consumption in Different Application Field (2018-2028)
5 North America
5.1 US Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
5.2 Canada Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
5.3 Mexico Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
6 Asia
6.1 China Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
6.2 Japan Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
6.3 India Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
6.4 Korea Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
6.5 Southeat Asia Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
7 Europe
7.1 Germany Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
7.2 UK Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
7.3 France Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
7.4 Russia Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
7.5 Italy Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
8 Middle East and Africa
8.1 Saudi Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
8.2 UAE Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
8.3 Egypt Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
8.4 Nigeria Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
8.5 South Africa Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
9 South America
9.1 Brazil Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
9.2 Argentina Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
9.3 Colombia Drugs for Non-Small Cell Lung Cancer Sales, Revenue and Growth Rate (2018-2028)
10 Global Drugs for Non-Small Cell Lung Cancer Average Price Trend
10.1 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in North America (2018-2028)
10.2 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Asia (2018-2028)
10.3 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Europe (2018-2028)
10.4 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in Middle East & Africa (2018-2028)
10.5 Market Price for Each Type of Drugs for Non-Small Cell Lung Cancer in South America (2018-2028)
11 Value Chain
11.1 Drugs for Non-Small Cell Lung Cancer Value Chain Analysis
11.1.1 Upstream
11.1.2 Downstream
11.2 COVID-19 Impact on Drugs for Non-Small Cell Lung Cancer Industry
11.2.1 Industrial Policy Issued Under the Epidemic Situation
11.2.2 Post-pandemic Era
11.3 Cost-Under the Epidemic Situation
11.3.1 Cost of Raw Material
11.4 Channel Analysis
11.4.1 Distribution Channel-Under the Epidemic Situation
11.4.2 Distributors
12 Major Players of Global Drugs for Non-Small Cell Lung Cancer Market, Competitive Analysis
12.1 Bristol-Myers Squibb
12.1.1 Bristol-Myers Squibb Company Profiles and Company News
12.1.2 Bristol-Myers Squibb Product Introduction
12.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.1.4 SWOT Analysis
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Company Profiles and Company News
12.2.2 GlaxoSmithKline Product Introduction
12.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.2.4 SWOT Analysis
12.3 Menarini
12.3.1 Menarini Company Profiles and Company News
12.3.2 Menarini Product Introduction
12.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.3.4 SWOT Analysis
12.4 Sanofi
12.4.1 Sanofi Company Profiles and Company News
12.4.2 Sanofi Product Introduction
12.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.4.4 SWOT Analysis
12.5 BioMarin Pharmaceutical
12.5.1 Ziopharm Oncology Company Profiles and Company News
12.5.2 Ziopharm Oncology Product Introduction
12.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.5.4 SWOT Analysis
12.6 Alchemia
12.6.1 Alchemia Company Profiles and Company News
12.6.2 Alchemia Product Introduction
12.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.6.4 SWOT Analysis
12.7 Amgen
12.7.1 Amgen Company Profiles and Company News
12.7.2 Amgen Product Introduction
12.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.7.4 SWOT Analysis
12.8 Apotex
12.8.1 Apotex Company Profiles and Company News
12.8.2 Apotex Product Introduction
12.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.8.4 SWOT Analysis
12.9 BioMarin Pharmaceutical
12.9.1 BioMarin Pharmaceutical Company Profiles and Company News
12.9.2 BioMarin Pharmaceutical Product Introduction
12.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.9.4 SWOT Analysis
12.10 CellAct Pharma
12.10.1 CellAct Pharma Company Profiles and Company News
12.10.2 CellAct Pharma Product Introduction
12.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales, Revenue (2018-2022)
12.10.4 SWOT Analysis
12.11 Cerulean Pharma
12.12 Cipla
12.13 Cornerstone Pharmaceuticals
12.14 Curis
12.15 CytRx
12.16 Eli Lilly
12.17 Exelixis
12.18 Fresenius Kabi
12.19 Genentech
12.20 Hikma Pharmaceuticals
12.21 Hospira
12.22 Intas Pharmaceuticals
12.23 Karyopharm Therapeutics
12.24 Kyowa Hakko Kirin
12.25 Ligand Pharmaceuticals
13 Global Drugs for Non-Small Cell Lung Cancer Market, Competitive Landscape and Market Forecast
13.1 Key Companies Dominating the Global Drugs for Non-Small Cell Lung Cancer Market
13.2 Concentration Ratio (CR5) of Global Drugs for Non-Small Cell Lung Cancer Market (2018)
13.2.1 Market Share of Top 5 Players in Term of Revenue (2018)
13.3 Concentration Ratio (CR5) of Global Drugs for Non-Small Cell Lung Cancer Market (2022)
13.3.1 Market Share of Top 5 Players in Term of Revenue (2022)
14 Conclusion
15 Methodology and Data Source
